Clinical application of expanded noninvasive prenatal testing for fetal chromosome abnormalities in a cohort of 39, 580 pregnancies. Issue 5 (2nd February 2022)

• Record Type: Journal Article
• Authors: Chen, Yisheng; Lu, Loukaiyi; Zhang, Ying; Wang, Feifei; Ni, Yinghua; Wang, Qiang; Ying, Chunmei
• Is Part Of: American journal of medical genetics. Volume 188:Issue 5(2022)
• Page Start: 1426
• Page End: 1434
• Publication Date: 2022-02-02
• Subjects: microdeletion and microduplication syndromes -- NIPT‐plus -- prenatal diagnosis -- trisomy; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.62657
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract: The aim of this study was to determine the predictive value of expanded noninvasive prenatal testing (NIPT‐plus) for fetal chromosome abnormalities in the second trimester (12–26 weeks). We conducted a retrospective cohort study of 39, 580 pregnancies with NIPT‐plus. Screening positive cases were diagnosed with karyotyping and single‐nucleotide polymorphism array analysis (SNP array)/copy number variation sequencing (CNV‐seq) with follow‐up. The positive predictive values (PPVs) of trisomy 21, 18, and 13 (T21, T18, and T13), sex chromosome aneuploidies (SCAs), and microdeletion and microduplication syndromes (MMS) by NIPT‐plus were recorded. We assessed the predictive value of NIPT‐plus based on maternal age and conventional indications. Of 39, 580 pregnancies with NIPT‐plus, 511 (1.3%) had prenatal screening positive results of fetal chromosome abnormality, of which 87.7% (448/511) had invasive prenatal diagnosis. NIPT‐plus performed better in predicting fetal SCAs and chromosome aneuploidies for pregnancies with advanced maternal age (AMA) than young maternal age (YMA). Besides, the PPVs of T21, T13, and chromosome aneuploidies showed an upward trend when comparison was based on maternal age in 5‐year subintervals. The termination rates of 45, X, 47, XXX, 47, XXY, and 47, XYY were 100% (11/11), 20.0% (3/15), 91.7% (22/24), and 7.1% (1/14) with postnatal follow‐up. Last but not least, the PPV for MMS is 41.7% (30/72), which may have a positive correlation between the size of CNVs. Pregnant women with screen‐positive results for common trisomies (T13, T18, and T21) were more willing to conduct invasive prenatal diagnosis compared to those with positive results for SCAs or MMS. However, the current study demonstrated SCAs and MMS had the lowest PPV. This highlights the importance of confirmatory prenatal diagnosis in those patients and the potential impact on genetic counseling and informative decision‐making.